人类棘球蚴病是由一种寄生虫，即棘球绦虫属绦虫所引起的人畜共患病（由动物传染给人类的疾病）。棘球蚴病有四种形式：
حقائق رئيسية
إن دواء المشوكات البشري هو مرض طفيلي تتسبب به شريطيات من جنس الشريطيات المشوكة.
وأهم شكلين لهذا المرض لدى الإنسان هما داء المشوكات الكيسي ( داء التكيس ...لديداني) وداء المشوكات السنخي.
ويصاب الإنسان بالعدوى عبر ابتلاع بيوض الطفيليات في الأغذية، أو المياه، أو التربة الملوثة، أو من خلال الاحتكاك المباشر مع الحيوانات المضيفة.
وغالباً ما يكون علاج داء المشوكات مكلفاً ومعقداً، وقد يتطلب جراحة واسعة و/أو علاجاً دوائياً مطولا.
وتشمل برامج الوقاية إخضاع الكلاب لتدابير طرد الديدان، والنهوض بمعاينة الأغذية ونظافة المسالخ؛ ويجري حالياً تقييم تطعيم الحملان كتدخل إضافي.
وهناك أكثر من مليون مصاب بداء المشوكات في أي وقت من الأوقات.
ومرض داء المشوكات البشري هو مرض حيواني المصدر (أي ينتقل إلى الإنسان من الحيوان) تتسبب به طفيليات هي شريطيات من جنس المشوكات. ويظهر داء المشوكات في أربعة أشكال:
more
Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are
estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co...nsequences of the lymphatic vessel impairment caused by infection with these parasites. Mosquitos in the genera Culex, Anopheles, Mansonia and Aedes transmit the parasites from person to person. 2020 marked the 20th year since WHO established the Global Programme to Eliminate Lymphatic Filariasis (GPELF) which aims to stop transmission of infection with mass drug administration (MDA) and to alleviate suffering among people affected by the disease through morbidity management and disability prevention (MMDP).
more
La filariose lymphatique (FL) est une maladie évitable, incapacitante et défigurante, due à une infestation par des filaires parasites des espèces Wuchereria bancrofti, Brugia malayi et B. timori. On estime que 51,4 millions de personnes sont infectées dans le monde. Le lymphœdème et l’hydr...ocèle sont les conséquences cliniques chroniques visibles de l’altération des vaisseaux lymphatiques causée par la présence de
ces parasites dans l’organisme. Les parasites sont transmis d’une personne à l’autre par l’intermédiaire de moustiques des genres Culex, Anopheles, Mansonia et Aedes. L’année 2020 a marqué la 20e année du Programme mondial pour l’élimination de la filariose lymphatique (GPELF) établi par l’OMS, dont l’objectif est de mettre fin à la transmission de l’infection grâce à l’administration de masse de médicaments
(AMM) et d’alléger les souffrances des malades par la prise en charge de la morbidité et la prévention des incapacités (PMPI).
more
Since the launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, more than 910 million people have received preventive chemotherapy for lymphatic filariasis (LF) and many thousands have received care for chronic manifestations of the disease. To achieve this, millions of c...ommunity drug distributors (CDDs), community members and health personnel have worked together each year to ensure that at-risk communities receive preventive chemotherapy through mass drug administration (MDA). The successes of 20 y of partnership with communities is celebrated, including the application of community-directed treatment, the use of CDDs and integration with other platforms to improve community access to healthcare. Important challenges facing the GPELF moving forward towards 2030 relate to global demographic, financing and programmatic changes. New innovations in research and practice present opportunities to encourage further community partnership to achieve the elimination of LF as a public health problem. We stress the critical need for community ownership in the current Covid-19 pandemic, to counter concerns in relaunching MDA programmes for LF.
more
The South-East Asia regional programme to eliminate lymphatic filariasis (LF) was launched in 2000. This study presents the progress and impact of the programme in the region.
Chagas heart disease (CHD) affects approximately 30% of patients chronically infected with the protozoa Trypanosoma cruzi. CHD is classified into four stages of increasing severity according to electrocardiographic, echocardiographic, and clinical criteria. CHD presents with a myriad of clinical man...ifestations, but its main complications are sudden cardiac death, heart failure, and stroke. Importantly, CHD has a higher incidence of sudden cardiac death and stroke than most other cardiopathies, and patients with CHD complicated by heart failure have a higher mortality than patients with heart failure caused by other etiologies. Among patients with CHD, approximately 90% of deaths can be attributed to complications of Chagas disease. Sudden cardiac death is the most common cause of death (55%-60%), followed by heart failure (25%-30%) and stroke (10%-15%). The high morbimortality and the unique characteristics of CHD demand an individualized approach according to the stage of the disease and associated complications the patient presents with. Therefore, the management of CHD is challenging, and in this review, we present the most updated available data to help clinicians and cardiologists in the care of these patients. We describe the clinical manifestations, diagnosis and classification criteria, risk stratification, and approach to the different clinical aspects of CHD using diagnostic tools and pharmacological and non-pharmacological treatments.
more
В дорожной карте по борьбе с забытыми тропическими болезнями на 2021–2030 гг. («дорожная карта») определены глобальные цели и основные этапы в отношении борьбы с 20 бол...знями и группами болезней, их элиминации или полной ликвидации. В ней также определены сквозные целевые показатели, согласованные с Тринадцатой общей программой работы ВОЗ и Целями в области устойчивого развития, а также стратегии по достижению этих целевых
показателей в течение ближайших десяти лет.
more
Despite pandemic-related disruptions, a total of 76.9 million people received treatment for schistosomiasis in 2020, representing a global coverage of 31.9%, compared with 105 million treated in 2019 (coverage of 44.8%).
The latest data published by the World Health Organization (WHO) show that 2...8.6 million fewer people were treated for schistosomiasis (bilharzia) in 2020 than in 2019. This 27% drop in the number of treatments delivered is largely due to the implementation of COVID-19 measures, including school closures.
more
Transactions of The Royal Society of Tropical Medicine and Hygiene, Volume 115, Issue 2, February 2021, Pages 136–144, https://doi.org/10.1093/trstmh/traa167.
Neglected tropical diseases (NTDs) are targeted for global control or elimination. Recognising that the populations most in need of medici...nes to target NTDs are those least able to support and sustain them financially, the pharmaceutical industry created mechanisms for donating medicines and expertise to affected countries through partnerships with the WHO, development agencies, non-governmental organisations and philanthropic donors. In the last 30 y, companies have established programmes to donate 17 different medicines to overcome the burden of NTDs.
more
Las enfermedades transmitidas por vectores (ETV) son enfermedades infecciosas propagadas por organismos intermediarios como insectos hematófagos, garrapatas, ácaros, caracoles y roedores, que transmiten virus, parásitos y bacterias a los seres humanos. Estas enfermedades son la causa de una notab...le carga de enfermedad y mortalidad, que afecta a las personas enfermas, sus familias y sus comunidades. En la presente publicación se revisan y actualizan los principales métodos e indicadores de vigilancia entomológica, así como las medidas de control vectorial utilizadas contra las ETV en la Región de las Américas. Su elaboración se inscribe en la misión de la Organización Panamericana de la Salud (OPS) de desarrollar actividades encaminadas a fortalecer la capacidad y las buenas prácticas entomológicas en salud pública de los países de la Región. Asimismo, el contenido se ha armonizado con los principios y fundamentos del marco estratégico mundial de la Organización Mundial de la Salud para el manejo integrado de vectores, adoptado como referencia técnica por la OPS para la organización y la estructuración de los programas de control de vectores en la Región. Se trata de un trabajo exhaustivo e integral que proporciona a los responsables de los programas nacionales de control vectorial, epidemiólogos, entomólogos y otros interesados directos acceso rápido a la información más relevante disponible.
more
The Global Leprosy Strategy 2021–2030 “Towards zero leprosy” was developed through a broad consultative process with all major stakeholders during 2019 and 2020. Valuable inputs were provided by national leprosy programme managers, technical agencies, public health and leprosy experts, funding... agencies and persons or members of communities directly affected by leprosy.
The Strategy aims to contribute to achieving the Sustainable Development Goals. It is structured along four pillars:
(i) implement integrated, country-owned zero leprosy road maps in all endemic countries;
(ii) scale up leprosy prevention alongside integrated active case detection;
(iii) manage leprosy and its complications and prevent new disability; and
(iv) combat stigma and ensure human rights are respected. Interruption of transmission and elimination of disease are at the core of the Strategy.
more
Technical Update
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection.... Preliminary
evidence suggests that HIV infection may increase the risk of BU disease (1–3). In the Médecins Sans Frontières project in Akonolinga, Cameroon, HIV prevalence was approximately 3–6 times higher among BU patients than the regional estimated HIV prevalence (2). Similarly in Benin and Ghana, BU
patients were 8 times and 3 times respectively more likely to have HIV infection than those without BU (1, 3). Further study is needed to clarify this association and enhance knowledge about the prevalence ofBU–HIV coinfection in endemic areas.
more
A total of 18 laboratories from 13 countries participated in the four rounds of EQA: 10 laboratories from eight African endemic countries, four of which participated in all four rounds and three in three rounds. The overall results showed that the median performance of these laboratories improved ov...er the four rounds. However, the proportion of laboratories reporting false–positive cases remains high and indicates a problem of specificity probably due to contamination. The proportion of laboratories reporting both false–positive and false–negative results raises the issue of the quality of the data reported by WHO in Africa as well as the results of the studies carried out in these different laboratories in various countries.
more
In this document, recommendations are provided on designing and implementing
a cross-sectional serosurvey using school-based sampling to estimate age-specific
DENV seroprevalence to inform a country’s national dengue vaccination program.
The document includes recommendations for methods for ...planning and conducting
serosurveys, including survey design, specimen collection, laboratory testing, data
analysis, and the interpretation and reporting of results.
more
The World Health Organization organized a Consultation of National Leprosy Programme managers, partners and affected persons to discuss the draft Global Leprosy Strategy, 2021--2030. This virtual event took place from 26 to 30 October 2020. It was attended by more than 450 stakeholders. Contribution...s were shared through 70 presentations made by stake holders from all Regions. The presentations covered the key strategic approaches: global context, challenges in countries, contact tracing and post exposure prophylaxis, disability care, interruption of transmission and elimination of disease, stigma and d iscrimination, research. In addition to numerous comments received through the chat box and by email, the conclusions and recommendations of this Consultation will guide finalizing the post 2020 Global Leprosy Strategy.
more
This document outlines the evaluation process that WHO undertakes to assess novel tools and strategies targeted at VBDs. Its aim is to articulate the linkage between the generation of evidence that demonstrates public health impact of novel interventions, and the development of policy recommendation...s based on the generated data. The document defines standards for the evaluation process, as well as the steps that an applicant needs to undertake, along with some guiding principles that aim to support applicants in the development of submissions with WHO.
more
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifa...mpicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8) is highly effective, but streptomycin injections are painful and potentially harmful. We aimed to compare the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with that of RS8 for treatment of early Buruli ulcer lesions.
more
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of... Buruli ulcer everywhere. However, this finding does not mean that
Buruli ulcer is cured at 8 weeks.
more
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery.
The targ...et set by the World Health Organization (WHO) for control of Buruli ulcer is for countries to achieve a rate of case confirmation by PCR of at least 70%. All endemic countries have at least one PCR facility to support confirmation of cases. However, most countries in the WHO African Region have not been able to reach the target, and the rate of case confirmation has been declining
more
